Selina Chen-Kiang, PhD
Palbociclib (Ibrance) has been shown to overcome ibrutinib (Imbruvica) resistance in primary human samples and mantle cell lymphoma (MCL) cell lines with the mutated BTKC481S protein. The use of this CDK4/6 inhibitor has sparked an investigation into combination therapies to target CDK4 in MCL, said Selina Chen-Kiang, PhD.
Although CDK4/6 inhibitors have been garnering attention in the breast cancer landscape, targeting CDK4 is a rational approach in MCL, as dysregulation of CDK4 and cyclin D1 underlies unrestrained proliferation of MCL cells, said Chen-Kiang. Additionally, targeting tumor cells in lymphoid malignancies offers a unique advantage over solid tumors, as the cells can be purified in real time.
... to read the full story